Skip to main content

Table 4 Cytotoxicity of ACT-101 conjugates with different linkers and DPRs in U937 cells

From: High anti-tumor activity of a novel alpha-fetoprotein-maytansinoid conjugate targeting alpha-fetoprotein receptors in colorectal cancer xenograft model

Conjugate

Average DPR

IC50** (nM) (n = 2)

ACT-101-ABZ982

2.5

5.25

ACT-101-ABZ982

3.8

5.29

ACT-101-ABZ982

5.5

1.71

ACT-101-ABZ982

6.3

6.55***

ACT-101-ABZ1827

3.4

7.07

ACT-101-ABZ1827

4.4

5.98

ACT-101-ABZ1827

5.9

2.93

Free Toxin (ABZ-981)

 

3.06

  1. DPR Drug to Protein Ratio; **IC50: the concentration of drug required for 50% growth inhibition; ***n = 1
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us